On-chip Mid-IR ATR and Raman Spectroscopies for Rapid Bedside Biomarker Diagnostics

用于快速床边生物标志物诊断的片上中红外 ATR 和拉曼光谱

• 批准号: 2621670
• 金额: --
• 依托单位: University of Southampton
• 依托单位国家: 英国
• 项目类别: Studentship
• 财政年份: 2019
• 资助国家: 英国
• 起止时间: 2019 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=studentship-2621670
• 关键词: chip; Mid; IR; ATR; Raman

There is a pressing need for diagnostic tools that can produce results quickly from patients' bedsides and in doctors' surgeries. Rapid, accurate results will allow rapid therapeutic decisions and save lives at reduced cost. In contrast, existing technologies require transfer of samples to centrally located laboratories equipped with sophisticated instruments, and highly skilled personnel. Both Mid-IR and Raman spectroscopies have been shown independently to be powerful biodiagnostic tool for specific biomarkers, however, combining the strengths of both these techniques on a single chip will take advantage of their complementarity in identifying disease causing biomarkers much more efficiently.The overall aim of this project is to develop the ATR/Raman chips using advanced materials and apply the chip for proof of principle demonstration for the diagnostics of neonatal respiratory distress syndrome (nRDS). In specific the project will involve computational modelling and design of these chips including signal enhancement features using resonating structures. This will be followed by fabrication of the chips in our cleanrooms based on materials such as silicon and plastics. Fabricated devices will be first characterised at the ORC and then applied to clinical diagnostic applications including nRDS in collaboration with University Hospital Southampton.

迫切需要能够在患者床边和医生手术中快速得出结果的诊断工具。快速、准确的结果将有助于快速做出治疗决策并以更低的成本挽救生命。相比之下，现有技术需要将样品转移到配备精密仪器和高技能人员的中心实验室。中红外和拉曼光谱均已被独立证明是针对特定生物标志物的强大生物诊断工具，但是，将这两种技术的优势结合在单个芯片上将利用它们的互补性，更有效地识别引起疾病的生物标志物。该项目的目的是使用先进材料开发ATR/拉曼芯片，并将该芯片应用于新生儿呼吸窘迫综合征（nRDS）诊断的原理验证演示。具体来说，该项目将涉及这些芯片的计算建模和设计，包括使用谐振结构的信号增强功能。随后将在我们的洁净室中基于硅和塑料等材料制造芯片。制造的设备将首先在 ORC 进行表征，然后与南安普顿大学医院合作应用于包括 nRDS 在内的临床诊断应用。